Sino Biological/Her2/ERBB2 Protein, Human, Recombinant (ECD, hFc Tag)/1/10004-H02H
商品编号：
10004-H02H
品牌：
sinobiological
市场价：
¥0.00
美元价：
0.00
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
Her2/ERBB2 Protein, Human, Recombinant (ECD, hFc Tag): Product Information
Purity
> 90 % as determined by SDS-PAGE
Endotoxin
< 1.0="" eu="" per="" μg="" of="" the="" protein="" as="" determined="" by="" the="" lal="">
Activity
1. Measured by its binding ability in a functional ELISA.Immobilized human ErbB2 at 2.5 μg/ml can bind Herceptin with a linear range of 3.2-80 ng/ml.2. Measured by its ability to block anti-ErbB2 mediated inhibition of BT474 human breast ductal carcinoma cell proliferation. The ED50 for this effect is 0.5-3 μg/mL in the presence of 0.6 µg/mL Anti-ErbB2/Her2 Monoclonal Antibody.
Protein Construction
A DNA sequence encoding the extracellular domain (Met 1-Thr 652) of human ErbB2 (NP_004439.2) was fused with the Fc region of human IgG1 at the C-terminus.
Accession#
NP_004439.2
Expressed Host
HEK293 Cells
Species
Human
Predicted N Terminal
Thr 23
Molecule Mass
The recombinant human ErbB2/Fc chimera is a disulfide-linked homodimeric protein generated by proteolytic removal of the signal peptide. The monomer comprises 868 amino acids and has a calculated molecular mass of 96.1 kDa. As a result of glycosylation, the monomer migrates as an approximately 130-140 kDa protein in SDS-PAGE under reducing conditions.
Formulation
Lyophilized from sterile PBS, pH 7.4Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
Her2/ERBB2 Protein, Human, Recombinant (ECD, hFc Tag): Images
Measured by its ability to block anti-ErbB2 mediated inhibition of BT474 human breast ductal carcinoma cell proliferation. The ED50 for this effect is 0.5-3 μg/mL in the presence of 0.6 µg/mL Anti-ErbB2/Her2 Monoclonal Antibody.
Measured by its binding ability in a functional ELISA. Immobilized human ErbB2 at 2.5 μg/ml can bind Herceptin with a linear range of 3.2-80 ng/ml.
Her2/ERBB2 Protein, Human, Recombinant (ECD, hFc Tag): Synonyms
CD340 Protein, Human; ENV Protein, Human; ENVW Protein, Human; ERVWE1 Protein, Human; HER-2 Protein, Human; HER-2/neu Protein, Human; HER2 Protein, Human; HERV-7q Protein, Human; HERV-W-ENV Protein, Human; HERV7Q Protein, Human; HERVW Protein, Human; HERVWENV Protein, Human; MLN 19 Protein, Human; MLN19 Protein, Human; NEU Protein, Human; NGL Protein, Human; TKR1 Protein, Human
Her2/ERBB2 Background Information
Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, NEU, and CD340, is a type I membrane glycoprotein and belongs to the epidermal growth factor (EGF) receptor family. HER2 protein cannot bind growth factors due to the lacking of ligand binding domain of its own and autoinhibited constitutively. However, HER2 forms a heterodimer with other ligand-bound EGF receptor family members, therefore stabilizes ligand binding and enhances kinase-mediated activation of downstream molecules. HER2 plays a key role in development, cell proliferation and differentiation. HER2 gene has been reported to associate with malignancy and a poor prognosis in numerous carcinomas, including breast, prostate, ovarian, lung cancers and so on.
- Cancer Immunotherapy
- Immune Checkpoint
- Immunotherapy
- Targeted Therapy
Full Name
erb-b2 receptor tyrosine kinase 2
Research Areas
- Cancer Drug Targets
- Receptor Tyrosine Kinases (RTKs)
References
- Krawczyk N, et al. (2009) HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res. 29(10): 4019-24.
Human Her2/ERBB2 Proteins
- Her2/ERBB2 Protein, Human, Recombinant (ECD, domain I, His Tag)10004-H08H1
- Her2/ERBB2 Protein, Human, Recombinant (ECD, domain IV, His Tag)10004-H08H4
- Her2/ERBB2 Protein, Human, Recombinant (His & AVI Tag), Biotinylated10004-H27H-B
- Her2/ERBB2 Protein, Human, Recombinant (aa 676-1255, His & GST Tag)10004-H20B1
- Her2/ERBB2 Protein, Human, Recombinant (ECD, His Tag), Biotinylated10004-H08H-B
- Her2/ERBB2 Protein, Human, Recombinant (ECD), Biotinylated10004-HCCH-B
- Her2/ERBB2 Protein, Human, Recombinant (hFc Tag), Biotinylated10004-H02H-B
- Her2/ERBB2 Protein, Human, Recombinant (ECD, His Tag), Biotinylated10004-H08H1-B
- Her2/ERBB2 Protein, Human, Recombinant (ECD, His Tag), Biotinylated10004-H08H4-B
- Her2/ERBB2 Protein, Human, Recombinant (ECD)10004-HCCH
- Her2/ERBB2 Protein, Human, Recombinant (ECD, His Tag)10004-H08H
Mouse Her2/ERBB2 Proteins
- Her2/ERBB2 Protein, Mouse, Recombinant (His Tag)50714-M08H
- Her2/ERBB2 Protein, Mouse, Recombinant (hFc Tag)50714-M02H
Rat Her2/ERBB2 Proteins
- Her2/ERBB2 Protein, Rat, Recombinant (hFc Tag)80079-R02H
- Her2/ERBB2 Protein, Rat, Recombinant (His Tag)80079-R08H
- Her2/ERBB2 Protein, Rat, Recombinant80079-RCCH
Cynomolgus Her2/ERBB2 Proteins
- Her2/ERBB2 Protein, Cynomolgus, Recombinant (His Tag)90295-C08H
- Her2/ERBB2 Protein, Cynomolgus, Recombinant (ECD, hFc Tag)90295-C02H
Rhesus Her2/ERBB2 Proteins
- Her2/ERBB2 Protein, Rhesus, Recombinant (hFc Tag)90020-K02H
- Her2/ERBB2 Protein, Rhesus, Recombinant (His Tag)90020-K08H
Canine Her2/ERBB2 Proteins
- Her2/ERBB2 Protein, Canine, Recombinant (His Tag)70024-D08H
- A new prodrug form of Affibody molecules (pro-Affibody) is selectively activated by cancer-associated proteasesAuthorL Sandersjöö, A Jonsson, J LöfblomYear2014JournalCellular and Molecular Life SciencesApplicationbindingPubMed ID: 25287047FoldedExpand
- Phage display as a tool for development of novel therapeutics for breast cancerAuthorCabral, MJCD;Year2014JournalThesisApplicationcoating proteinFoldedExpand
- Efficient production of Trastuzumab Fab antibody fragments in Brevibacillus choshinensis expression systemAuthorMizukami, M;Onishi, H;Hanagata, H;Miyauchi, A;Ito, Y;Tokunaga, H;Ishibashi, M;Arakawa, T;Tokunaga, M;Year2018JournalProtein Expr. Purif.ApplicationELISAPubMed ID: 29857036FoldedExpand
- Harnessing iNKT and CD8 T cells for Immunotherapy of CancerAuthorTschumi, BO;Year2018JournalThesisApplicationFAC (CAR-T)FoldedExpand
- High affinity single-chain variable fragments are specific and versatile targeting motifs for extracellular vesiclesAuthorLongatti, A;Schindler, C;Collinson, A;Jenkinson, L;Matthews, C;Fitzpatrick, L;Blundy, M;Minter, R;Vaughan, T;Shaw, M;Tigue, N;Year2018JournalNanoscaleApplicationELISAPubMed ID: 30010165FoldedExpand
- Multiplex competitive analysis of HER2 and EpCAM cancer markers in whole human blood using Fe2O3@Ag nanocompositeAuthorBalzerová, A;Opletalová, A;Ranc, V;Zbořil, R;Year2018JournalApplied Materials TodayApplicationbindingFoldedExpand
- Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeuticsAuthorHarth, S;Ten Haaf, A;Loew, C;Frisch, C;Knappik, A;Year2018JournalMAbsApplicationELISAPubMed ID: 30516449FoldedExpand
- Site-specific conjugation of recognition tags to trastuzumab for Peptide Nucleic Acid-mediated radionuclide HER2 pretargetingAuthorWesterlund, K;Vorobyeva, A;Mitran, B;Orlova, A;Tolmachev, V;Karlström, A;Altai, M;Year2019JournalBiomaterialsApplicationSPRPubMed ID: 30877838FoldedExpand
If you couldn"t find the specific citation, you can:
- Find All Citations
- Submit a CitationGet a Publication Reward
- Leave Us a Message
E.coli protein expression service
Mammalian transient protein expression service
Baculovirus-insect expression service
Stable cell line development service (CHO / HEK293)
品牌介绍
北京义翘神州科技股份有限公司（Sino Biological Inc.）是一家从事生物试剂研发、生产、销售并提供技术服务的生物科技公司，主要业务包括重组蛋白、抗体、基因和培养基等产品，以及重组蛋白、抗体的开发和生物分析检测等服务。义翘神州为全球的药品研发企业和生命科学研究机构提供高质量的生物试剂产品和高水平的技术服务。公司目前生产和销售的现货产品种类超过 4.6 万种，其中重组蛋白约 6,000 种，包括超过 3,800 种人源细胞表达重组蛋白产品，能够全面满足客户对于最接近人体天然蛋白结构和性质的重组蛋白需求；公司还能提供约 12,000 种抗体，其中单克隆抗体数量约 4,600 种，能够覆盖生命科学研究的多个领域，为分子生物学、细胞生物学、免疫学、发育生物学、干细胞研究等基础科研方向和创新药物研发提供「一站式」生物试剂产品和技术服务。义翘神州的客户涵盖大学、科研院所、医药研发企业等国内外各类生物研发单位。目前公司已经在美国、欧洲建立了子公司，已成为生物试剂行业国内领先的科技公司之一。
联络我们
